Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases

2009 ◽  
Vol 2009 ◽  
pp. 29-30
Author(s):  
B. Hutton
Keyword(s):  
Mycophenolate Mofetil ◽  
Retrospective Study ◽  
Lupus Nephritis ◽  
Primary Treatment ◽  
Proliferative Disease ◽  
Membranous Lupus Nephritis

Approach to Membranous Lupus Nephritis: A Survey of Pediatric Nephrologists and Pediatric Rheumatologists

2017 ◽  
Vol 44 (11) ◽  
pp. 1619-1623 ◽  
Author(s):  
Alexis Boneparth ◽  
Suhas M. Radhakrishna ◽  
Larry A. Greenbaum ◽  
Eric Yen ◽  
Daryl M. Okamura ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Mycophenolate Mofetil ◽  
Lupus Nephritis ◽  
Pediatric Nephrology ◽  
Survey Study ◽  
Treatment Practices ◽  
Childhood Arthritis ◽  
American Society ◽  
Research Alliance ◽  
Membranous Lupus Nephritis

Objective.To describe treatment practices for childhood pure membranous lupus nephritis (MLN).Methods.Survey study of Childhood Arthritis and Rheumatology Research Alliance and American Society of Pediatric Nephrology members.Results.There were 117 respondents who completed the survey (60 pediatric nephrologists, 57 pediatric rheumatologists). Steroids and nonsteroid immunosuppression (NSI) were routinely used by the majority for MLN. Mycophenolate mofetil was the favored initial NSI. Nephrologists used steroids (60% vs 93%) and NSI (53% vs 87%) less often than did rheumatologists for MLN without nephrotic syndrome (NS).Conclusion.Pediatric rheumatologists and nephrologists both recommend steroids and NSI for children with MLN, with or without NS.

Pilot 24 month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome

Nephrology ◽  
2012 ◽  
Vol 17 (4) ◽  
pp. 352-357 ◽  
Author(s):  
DESMOND YH YAP ◽  
XUEQING YU ◽  
XIANG-MEI CHEN ◽  
FUMING LU ◽  
NAN CHEN ◽  
...  
Keyword(s):  
Nephrotic Syndrome ◽  
Mycophenolate Mofetil ◽  
Lupus Nephritis ◽  
Membranous Lupus Nephritis

Percutaneous sclerotherapy for spongiform venous malformations – analysis of patient-evaluated outcome and satisfaction

VASA ◽  
2017 ◽  
Vol 46 (6) ◽  
pp. 477-483
Author(s):  
Robert Karl Clemens ◽  
Frederic Baumann ◽  
Marc Husmann ◽  
Thomas Oleg Meier ◽  
Christoph Thalhammer ◽  
...  
Keyword(s):  
Retrospective Study ◽  
Medical Records ◽  
Venous Malformation ◽  
Primary Treatment ◽  
Venous Malformations ◽  
Treated Area ◽  
Item Questionnaire ◽  
Percutaneous Sclerotherapy ◽  
Multiple Treatments ◽  
Pain Improvement

Abstract. Background: Congenital venous malformations are frequently treated with sclerotherapy. Primary treatment goal is to control the often size-related symptoms. Functional impairment and aesthetical aspects as well as satisfaction have rarely been evaluated. Patients and methods: Medical records of patients who underwent sclerotherapy of spongiform venous malformations were reviewed and included in this retrospective study. The outcome of sclerotherapy as self-reported by patients was assessed in a 21 item questionnaire. Results: Questionnaires were sent to 166 patients with a total of 327 procedures. Seventy-seven patients (48 %) with a total of 159 procedures (50 %) responded to the survey. Fifty-seven percent of patients were male. The age ranged from 1 to 38.1 years with a median age of 16.4 years. The lower extremities were the most common treated area. Limitations caused by the venous malformation improved in the majority of patients (e.g. pain improvement 87 %, improvement of swelling 83 %) but also worsening of symptoms occurred in a minority of cases. Seventy-seven per cent would undergo sclerotherapy again. Conclusions: Sclerotherapy for treatment of venous malformations results in significant reduction of symptoms. Multiple treatments are often needed, but patients are willing to undergo them.

Sign in / Sign up

Export Citation Format

Share Document